Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023
公司普通股將於今天（2023 年 3 月 1 日）開始在納斯達克全球精選市場以新股票代碼「ZVRA」開始交易
New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community
新公司名稱 Zevra 是希臘語的斑馬，是罕見疾病社區國際公認的象徵
CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023.
慶祝活動，佛拉，2023 年 3 月 1 日（全球美通社）-Zevra 治療公司（NASDAQ：ZVRA）（「Zevra」或「公司」以前 KemPharm，Inc.），今天宣布，它將於今天 3 月 1 日在全球精選市場上開始以新股票代號「ZVRA」開始交易。。
The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwavering commitment to the rare disease community as it pursues its primary mission to deliver life-changing treatments to people with rare conditions, their families and caregivers who desperately need better options.
該公司的新公司名稱以及相應的股票代號，體現了 Zevra 對罕見疾病社區的堅定承諾，因為它追求其主要使命是為罕見條件的人，他們的家人和照顧者提供改變生活的治療方法，他們迫切需要更好的選擇。
Zevra is currently developing arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick type C disease ("NPC"). NPC, a rare disease with no currently approved treatments in the U.S., primarily affects children and is often fatal, causing progressive loss of brain, nerve, liver, spleen, bone marrow, and lung functions. The U.S. Food and Drug Administration ("FDA") has granted arimoclomol orphan drug designation, Fast Track designation, and rare pediatric disease designation for the treatment of NPC.
Zevra 目前正在開發阿里莫洛莫爾，這是一種口頭交付的一流研究產品候選產品，用於治療 C 型尼曼匹克疾病（「NPC」）。鼻咽癌是一種罕見的疾病，在美國目前沒有獲得批准的治療方法，主要影響兒童，並且通常是致命的，導致腦，神經，肝臟，脾臟，骨髓和肺功能逐漸喪失。美國食品和藥物管理局（「FDA」）已授予阿里莫洛莫爾孤兒藥物名稱，快速通道名稱和罕見的兒科疾病指定，用於治療鼻咽癌。
In addition, Zevra is also advancing KP1077, a product candidate based on Zevra's prodrug of d-methylphenidate, serdexmethylphenidate ("SDX"), which is currently being evaluated in a Phase 2 trial for the treatment of idiopathic hypersomnia ("IH"), a rare sleep disorder. Pending the results from that trial, the Company plans to conduct a pivotal Phase 3 study in IH, with the potential to study an expanded indication in narcolepsy.
此外，Zevra 還在推進 KP1077，這是一種基於 Zevra 的 d-苯甲酸酯前藥，舍德甲基苯硝酸酯（「SDX」）的候選產品，該產品目前正在用於治療特發性嗜睡（「IH」）的 2 期試驗中進行評估，這是一種罕見的睡眠障礙。在該試驗結果之前，該公司計劃在 IH 中進行一項關鍵的 3 階段研究，有潛力研究嗜睡症的擴大指示。
Zevra expects several key milestones in 2023, including the planned resubmission of the New Drug Application ("NDA") for arimoclomol to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of one or more certain commercial sales milestones for our partnered asset, AZSTARYS, during FY 2023.
Zevra 預計 2023 年有幾個關鍵里程碑，包括計劃在 2023 年第三季將阿里莫洛莫爾的新藥申請（「NDA」）重新提交給 FDA，KP1077 在 IH 中的臨時和最終數據讀數，以及我們合作資產 AZSTARYS 在 2023 財年期間的一個或多個特定商業銷售里程碑的潛在成就。
Visit Zevra's new corporate website at zevra.com to learn more.
訪問 Zevra 的新企業網站 zevra.com 了解更多信息。